Search
Magnesium hydroxide
go.drugbank.com/drugs/DB09104ApprovedInvestigationalMagnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. … Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form.
Mixtures: ACİDPASS 10 MG/800 MG/165 MG ÇİĞNEME TABLETİ, 2 ADET, TRIGAST 10 MG/800 MG/165 MG ÇİĞNEME TABLETİ, 6 ADETProducts: MAGNESIE CALCINEE SABA 400 MG SÜSPANSİYON HAZIRLAMAK İÇİN TOZ, 100 G, MAGNESIE CALCİNEE 400 MG SÜSPANSİYON HAZIRLAMAK İÇİN KURU TOZ, 100 GBenzalkonium
go.drugbank.com/drugs/DB11105ApprovedInvestigationalWhen used as an ingredient in antiseptic and disinfectant products however, it is an active antimicrobial agent [L1806]. … Benzalkonium is more commonly contained in consumer products in its salt form, benzalkonium chloride [FDA Label].
Mixtures: BENZAL EN POLVO, Dorithricin Halstabletten Classic 0,5 mg / 1,0 mg / 1,5 mg LutschtablettenCategories: Disinfectants (For Agents Used on Object), Compounds used in a research, industrial, or household settingClofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Categories: Heterocyclic Compounds, 2-RingSynonyms: (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol, 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenineSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersSynonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-oneBortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigational[L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995. … [A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acidVismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalIn July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803] … Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells.
Synonyms: 2-chloro-N-(4-chloro-3-pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925.
Categories: Compounds used in a research, industrial, or household settingProducts: NOVİLS 250 MG SERT KAPSÜL, 100 ADET, WİLENTİN 250 MG SERT KAPSÜL, 100 ADETObinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521] … [L54521] It was developed as a Type II anti-CD20 antibody to improve upon first-generation agents like rituximab.
Categories: CD20 (Clusters of Differentiation 20) inhibitorsProducts: GAZYVA 1000 MG/ 40 ML CONCENTRATE FOR SOLUTION FOR INFUSION, GAZYVA ® CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN 1000 MG / VIAL 40 MLPergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnIt is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. … It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy.
Categories: Adrenergic alpha-2 Receptor Agonists, Heterocyclic Compounds with 4 or More RingsProducts: PERGOLIDE EG, PERGOLID-NEURAX 1 MGModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalThe exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular … Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy.
Synonyms: 2-((diphenylmethyl)sulfinyl)acetamideCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Substrates